Screening method
The present invention provides a screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof.
1 . A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof.
2 . A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the amino acid sequence represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof.
3 . The screening method according to claim 1 , wherein the protein has the amino acid sequence represented by SEQ ID NO: 2.
4 . The screening method according to claim 1 , wherein the disease is a renal disease.
5 . The screening method according to claim 4 , wherein the renal disease is an Egr-1 depending renal disease.
6 . The screening method according to claim 4 , wherein the renal disease is diabetic nephropathy.
7 . The screening method according to claim 1 , which is characterized by comparing production of a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 and the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of a test compound.
8 . The screening method according to claim 1 , which is characterized by comparing an activity of a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of and in the absence of a test compound.
9 . The screening method according to claim 8 , wherein the activity is a binding activity to the polynucleotide, to which the protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 are capable of binding.
10 . The screening method according to claim 8 , wherein the activity is an expression-controlling activity of a gene under the control of transcriptional control by a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
11 . The screening method according to claim 1 , which is characterized by measuring and comparing production of a protein or salts thereof comprising the same or substantially the same amino acid sequences as that represented by SEQ ID NO: 1, and a binding activity to a polynucleotide, to which the protein or salts thereof is capable of binding, using the polynucleotide and an antibody against the protein or salts thereof in the case where a cell is cultivated that has the capability of producing the protein or salts thereof and the case where the cell is cultivated in the presence of a test compound.
12 . A compound or salts thereof obtained by the screening method according to claim 1 .
13 . A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a compound or salts thereof obtained by the screening method according to claim 1 .
14 . A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using a polynucleotide comprising a base sequence or a partial sequence thereof encoding a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
15 . A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using a polynucleotide comprising a base sequence or a partial sequence thereof encoding a protein or salts thereof comprising the amino acid sequence as that represented by SEQ ID NO: 1.
16 . The screening method according to claim 14 , wherein the polynucleotide comprises a base sequence or a partial sequence thereof represented by SEQ ID NO: 3 or SEQ ID NO: 4.
17 . The screening method according to claim 14 , wherein the disease is a renal disease.
18 . The screening method according to claim 17 , wherein the renal disease is an Egr-1 depending renal disease.
19 . The screening method according to claim 17 , wherein the renal disease is diabetic nephropathy.
20 . The screening method according to claim 14 , which is characterized by comparing the level of RNA encoding a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 and the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of a test compound.
21 . A compound or salts thereof obtained by the screening method according to claim 14 .
22 . A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a compound or salts thereof obtained by the screening method according to claim 14 .
23 . An antibody against a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
24 . A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises the antibody according to claim 23 .
25 . A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a polynucleotide having a complementary base sequence to the base sequence encoding a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, or its partial sequence.
26 . A diagnostic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises the antibody according to claim 23 .
27 . A diagnostic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a polynucleotide having the base sequence or its partial sequence encoding a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
28 . A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by comprising a polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6.
29 . The prophylactic and therapeutic product according to claim 28 , wherein the disease is a renal disease.
30 . The prophylactic and therapeutic product according to claim 29 , wherein the renal disease is an Egr-1 depending renal disease.
31 . The prophylactic and therapeutic product according to claim 29 , wherein the renal disease is diabetic nephropathy.
32 . A prophylactic and therapeutic product for diabetic nephropathy comprising a suppressor of Egr-1.
33 . The prophylactic and therapeutic product according to claim 32 , wherein the suppressor of Egr-1 is a suppressor of renal Egr-1.
34 . A method for the prophylaxis and treatment of diabetic nephropathy in a mammal, which is characterized by administering a suppressor of Egr-1 to the mammal.
35 . The method according to claim 34 , wherein the suppressor of Egr-1 is a suppressor of renal Egr-1.
36 . Use of a suppressor of Egr-1 for the manufacture of a prophylactic and therapeutic product for diabetic nephropathy.
37 . The use according to claim 36 , wherein the suppressor of Egr-1 is a suppressor of renal Egr-1.